May 30, 2024 – Page 2 – Goldea Capital

Cansortium Reports First Quarter 2024 Results

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

– Q1 Revenue up 14% YoY to $25.2 Million – 10th Consecutive Quarter of Positive Cash Flow from Operations TAMPA, Fla., May 30, 2024 (GLOBE NEWSWIRE) — Cansortium Inc. (CSE: TIUM.U) (OTCQB: CNTMF) (“Cansortium” or the “Company”), a vertically-integrated, multi-state cannabis company operating under the FLUENT™ brand, today announced financial and operating results for the first quarter ended March 31, 2024. Unless otherwise indicated, all financial results are presented in U.S. dollars. “We delivered another quarter of year-over-year revenue growth and positive cash flow generation during the first quarter as we continued to execute on our growth objectives,” said CEO Robert Beasley. “We are making the critical investments needed to lay the foundation for growth and support our future plans and remain excited...

RomReal: First quarter (q1) 2024 Results and Investor Presentation

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

RomReal hereby announces the results of the first quarter 2024 via the Report and an Investor presentation attached to this message. For further information, pls contact investors@romreal.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments RomReal Q1 2024 Report RomReal Q1 2024 Presentation

FRNT Financial Provides Business Update Amid Improving Conditions, Adds Context to Revenue Timing Volatility

Written by Customer Service on May 30, 2024. Posted in Public Companies.

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES TORONTO, May 30, 2024 (GLOBE NEWSWIRE) — FRNT Financial Inc. (TSXV: FRNT) (OTCQB:FRFLF) (FSE:XZ3) (the “Company” or “FRNT”) is pleased to provide a business update as macro and cryptocurrency-market conditions improve. The Company is seeing a significant uptick in business pipeline beyond what has been seen historically, though experiencing volatility in the timing of revenue realization. While such volatility is to be expected as the industry emerges from aggressive bear-market conditions, the Company believes the revenue-generation potential of the business has re-rated and that recurring, more predictable quarterly figures are on the horizon. Advisory & Consulting FRNT Financial has entered into a number of engagements, advising...

Sotera Health Announces Closing of $1.5 Billion Term Loan B and $750 Million Senior Secured Note Financings

Written by Customer Service on May 30, 2024. Posted in Public Companies.

CLEVELAND, May 30, 2024 (GLOBE NEWSWIRE) — Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced that its direct subsidiary has successfully closed a new senior secured Term Loan B facility in an aggregate principal amount of $1.51 billion (the “TLB”) as well as an issuance of senior secured notes in an aggregate principal amount of $750.0 million (the “Notes”) (collectively, the “Financings”), both of which mature in 2031. The Company used the net proceeds from the Financings, along with cash on hand, to refinance its existing $1.76 billion Term Loan B and $496.3 million Term Loan B facilities. “We are pleased to announce the successful refinancing...

Petrus Announces Results of Annual General Meeting of Shareholders

Written by Customer Service on May 30, 2024. Posted in Public Companies.

CALGARY, Alberta, May 30, 2024 (GLOBE NEWSWIRE) — Petrus Resources Ltd. (“Petrus” or the “Company“) (TSX: PRQ) is pleased to announce that its shareholders approved all resolutions at its annual general meeting of shareholders held May 29, 2024 (the “Meeting“). The resolutions approved at the Meeting were as follows: The resolution to fix the number of directors of the Company to be elected at the Meeting at five (5) directors was approved. The resolution to appoint the five (5) nominees as directors of the Company to serve until the next annual meeting of shareholders of the Company, was passed by way of ballot and the directors received the following votes: Nominee Outcome of Vote Votes For % For Votes Withheld % Withheld Donald Gray Elected 93,085,491 97.72% 2,169,375 2.28% Donald...

D-BOX Technologies’ Fourth Quarter Caps Record Year for Revenue and Net Profit

Written by Customer Service on May 30, 2024. Posted in Earnings Releases And Operating Results.

Haptics leader is focused on accelerating profitable growth MONTREAL, May 30, 2024 (GLOBE NEWSWIRE) — D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX: DBO) a world leader in haptic and immersive experiences, today reported financial results for the fourth quarter and fiscal year ended March 31, 2024. All dollar amounts are expressed in Canadian currency. Q4 FISCAL 2024 HIGHLIGHTS(Compared to Q4 fiscal 2023) Total revenues of $10.1 million contributed to full year record highs for rights for use, rental and maintenance revenue, system sales revenue, and total revenues 31 net new screens installed, bringing the total number of active D-BOX cinema screens to 929 as at March 31, 2024 Adjusted EBITDA decreased slightly from $648 thousand to $619 thousand Net profit of $620 thousand contributed to record net...

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

Written by Customer Service on May 30, 2024. Posted in Public Companies.

SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1 QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases with a high unmet need With QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has granted marketing authorization under exceptional circumstances and maintained orphan designation for QALSODY® (tofersen) for the treatment of adults with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene...

BurgerFi to Consider Strategic Alternatives

Written by Customer Service on May 30, 2024. Posted in Public Companies.

Designates David Heidecorn as successor to Ophir Sternberg as Chairman of the Board Enters retention agreements with executive leadership to ensure steady leadership FORT LAUDERDALE, Fla., May 30, 2024 (GLOBE NEWSWIRE) — BurgerFi International, Inc. (NASDAQ: BFI, BFIIW) (“BurgerFi” or the “Company”), owner of the high-quality, casual dining pizza brand under the name Anthony’s Coal Fired Pizza & Wings (“Anthony’s”) and one of the nation’s leading fast-casual “better burger” dining concepts through the BurgerFi brand, announced today several key initiatives with the goal of enhancing the Company’s prospects and ensuring stable Management as the Company goes through the process of reviewing strategic alternatives. The Board of Directors of BurgerFi has formed a special committee of Directors and retained Kroll Securities, LLC...

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

Written by Customer Service on May 30, 2024. Posted in Public Companies.

GAITHERSBURG, Md. and NESS ZIONA, Israel, May 30, 2024 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it received written notification (“the Notice”) from the NYSE American LLC (“NYSE American”), dated May 23, 2024, stating that the Company is no longer in compliance with continued listing standards, as set forth in Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”). Generally, Section 1003(a)(i) requires a listed company to have stockholders’ equity of $2 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years....

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

Written by Customer Service on May 30, 2024. Posted in Public Companies.

Late-breaking presentation of data at American Transplant Congress on Monday, June 3 Data show potential to monitor for therapeutic efficacy and recurrence Potential repeat testing opportunities with claims expansion IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine. Oncocyte’s Drs. Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study. VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study (NCT05021484) of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection (AMR), a leading cause...

Day: May 30, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice